Tg Therapeutics (TGTX) Net Cash Flow (2011 - 2026)
Tg Therapeutics (TGTX) posted quarterly Net Cash Flow of $363.1 million for Q1 2026, up 860.34% year-over-year from $37.8 million in Q1 2025, and up 7047.07% quarter-over-quarter from $5.1 million in Q4 2025.
Tg Therapeutics (TGTX) Net Cash Flow (2011 - 2026) Analysis & Trends
Tg Therapeutics' Net Cash Flow history runs 16 years deep, the most recent figure standing at $363.1 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 860.34% year-over-year to $363.1 million; the TTM figure through Mar 2026 stood at $310.1 million (up 447.19% YoY), while the FY2025 annual figure was -$100.7 million, down 215.78% from the prior year.
- Net Cash Flow for Q1 2026 stood at $363.1 million, up from $5.1 million in the prior quarter.
- The five-year high for Net Cash Flow was $363.1 million in Q1 2026, with the low at -$113.2 million in Q1 2022.
- The 5-year median for Net Cash Flow is -$15.9 million (2024), against an average of $8.4 million.
- The sharpest annual moves came in 2023 and 2026: Net Cash Flow slumped 667.56% in 2023, then soared 860.34% in 2026.
- Tg Therapeutics' Net Cash Flow stood at -$7.6 million in 2022, then plunged by 667.56% to -$58.0 million in 2023, then surged by 72.53% to -$15.9 million in 2024, then jumped by 131.9% to $5.1 million in 2025, then surged by 7047.07% to $363.1 million in 2026.
- Business Quant data shows TGTX's Net Cash Flow at $363.1 million in Q1 2026, $5.1 million in Q4 2025, and -$55.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 40.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.38 Mn |
| Jun 30, 2026 | 40.38 Mn |
| Mar 31, 2026 | 363.07 Mn |
| Mar 31, 2026 | 363.07 Mn |
| Dec 31, 2025 | 5.08 Mn |
| Dec 31, 2025 | 5.08 Mn |
| Sep 30, 2025 | -55.03 Mn |
| Sep 30, 2025 | -55.03 Mn |
| Jun 30, 2025 | -3.00 Mn |
| Jun 30, 2025 | -3.00 Mn |
| Mar 31, 2025 | -47.75 Mn |
| Mar 31, 2025 | -47.75 Mn |
| Dec 31, 2024 | -15.93 Mn |
| Dec 31, 2024 | -15.93 Mn |
| Sep 30, 2024 | 112.92 Mn |
| Sep 30, 2024 | 112.92 Mn |
| Jun 30, 2024 | 7.44 Mn |
| Jun 30, 2024 | 7.44 Mn |
| Mar 31, 2024 | -17.45 Mn |
| Mar 31, 2024 | -17.45 Mn |